中新经纬8月20日电 20日，借着创新药板块大涨，中国生物制药有限公司(下称中国生物制药)的总市值重回千亿港元，至收盘，股价上涨12.53%，总市值约1007亿港元。 此前一天，该公司公布了2026年中期业绩，上半年实现收入194.4亿元人民币，同比增长10.6%；基本溢利达到33.4亿元，同比增长8.1%，扣除投资持有的科兴中维的股息收入后基本溢利同比增长92.3%。 中国生物制药表示，...
Source Link中新经纬8月20日电 20日，借着创新药板块大涨，中国生物制药有限公司(下称中国生物制药)的总市值重回千亿港元，至收盘，股价上涨12.53%，总市值约1007亿港元。 此前一天，该公司公布了2026年中期业绩，上半年实现收入194.4亿元人民币，同比增长10.6%；基本溢利达到33.4亿元，同比增长8.1%，扣除投资持有的科兴中维的股息收入后基本溢利同比增长92.3%。 中国生物制药表示，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.